Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.56 |
| ▸ | SCN1A | P35498 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3910337 | 0.87 | SCN1A (0.58) | ALDH1A1POLBHRH3SCN1ASCN2A | |
| SCHEMBL11756971 | 0.84 | LMNA (0.61) | POLBSCN1ASCN2ASCN3A | |
| SCHEMBL24244916 | 0.83 | SCN1A (0.56) | POLBHRH3SCN1ASCN2ASCN3A | |
| SCHEMBL3310132 | 0.83 | HRH3 (0.47) | ALDH1A1POLBHRH3 | |
| SCHEMBL6539173 | 0.83 | SCN1A (0.55) | ALDH1A1POLBHRH3SCN1ASCN2A | |
| SCHEMBL11758763 | 0.83 | PARP10 (0.59) | HRH3SCN1ASCN2ASCN3AMEN1 | |
| SCHEMBL20046236 | 0.82 | GPR119 (0.55) | HRH3 | |
| SCHEMBL16702533 | 0.82 | HRH3 (0.61) | HRH3 | |
| SCHEMBL6134929 | 0.82 | MKNK1 (0.47) | ALDH1A1POLBHRH3 | |
| SCHEMBL6134754 | 0.82 | HRH3 (0.45) | ALDH1A1POLBHRH3SCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1366066-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072621-A2 | CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | ALDH1A1 3841/4885POLB 1754/4885HRH3 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.